Given the pivotal role of IL-1 family-driven inflammation in a wide range of pathologies, several IL-1-targeting therapies have been developed, including anakinra, canakinumab (anti-IL-1β mAb)), and rilonacept (a soluble IL-1 receptor chimeric fusion protein neutralizing IL-1α and IL-1β), which have received approval from both the United States Food and Drug Administration (FDA) and the European Medicines Association (EMA) for the treatment of various autoinflammatory and autoimmune conditions [153]. The gene discussed is IL1A; the disease is Autoimmunity.